JP2016527901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527901A5 JP2016527901A5 JP2016534802A JP2016534802A JP2016527901A5 JP 2016527901 A5 JP2016527901 A5 JP 2016527901A5 JP 2016534802 A JP2016534802 A JP 2016534802A JP 2016534802 A JP2016534802 A JP 2016534802A JP 2016527901 A5 JP2016527901 A5 JP 2016527901A5
- Authority
- JP
- Japan
- Prior art keywords
- test method
- cells
- mammal
- cancer
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010998 test method Methods 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 210000000130 stem cell Anatomy 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 102000057860 human MUC1 Human genes 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 210000001082 somatic cell Anatomy 0.000 claims 2
- 101001128739 Homo sapiens Nucleoside diphosphate kinase 6 Proteins 0.000 claims 1
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 1
- 102100032113 Nucleoside diphosphate kinase 6 Human genes 0.000 claims 1
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019152467A JP6902577B2 (ja) | 2013-08-12 | 2019-08-23 | 腫瘍成長を増強する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865092P | 2013-08-12 | 2013-08-12 | |
| US61/865,092 | 2013-08-12 | ||
| USPCT/US2014/017515 | 2014-02-20 | ||
| PCT/US2014/017515 WO2014130741A2 (en) | 2013-02-20 | 2014-02-20 | Nme inhibitors and methods of using nme inhibitors |
| PCT/US2014/050773 WO2015023694A2 (en) | 2013-08-12 | 2014-08-12 | Method for enhancing tumor growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152467A Division JP6902577B2 (ja) | 2013-08-12 | 2019-08-23 | 腫瘍成長を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527901A JP2016527901A (ja) | 2016-09-15 |
| JP2016527901A5 true JP2016527901A5 (enExample) | 2017-09-28 |
| JP6640086B2 JP6640086B2 (ja) | 2020-02-05 |
Family
ID=52468797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534802A Active JP6640086B2 (ja) | 2013-08-12 | 2014-08-12 | 腫瘍成長を増強する方法 |
| JP2019152467A Active JP6902577B2 (ja) | 2013-08-12 | 2019-08-23 | 腫瘍成長を増強する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152467A Active JP6902577B2 (ja) | 2013-08-12 | 2019-08-23 | 腫瘍成長を増強する方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4233536B1 (enExample) |
| JP (2) | JP6640086B2 (enExample) |
| CN (1) | CN105764334B (enExample) |
| AU (2) | AU2014306778B2 (enExample) |
| CA (1) | CA2921187A1 (enExample) |
| IL (1) | IL244093B (enExample) |
| TW (1) | TWI659210B (enExample) |
| WO (1) | WO2015023694A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3352566A4 (en) * | 2015-09-23 | 2019-07-31 | Minerva Biotechnologies Corporation | SCREENING METHOD FOR ACTIVE SUBSTANCES FOR DIFFERENTIATING STEM CELLS |
| IL302144A (en) | 2017-03-29 | 2023-06-01 | Minerva Biotechnologies Corp | Agents for stem cell differentiation and cancer treatment |
| CN108434452A (zh) * | 2018-03-13 | 2018-08-24 | 安徽瀚海博兴生物技术有限公司 | 一种将pd-1抗体和jmjd6联合用于制备抗癌药物的应用 |
| KR20230028796A (ko) | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| AU2023253692A1 (en) | 2022-04-12 | 2024-11-14 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| WO2025049494A1 (en) | 2023-08-29 | 2025-03-06 | Minerva Biotechnologies Corporation | Bacterial nme7 orthologs and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| CA2656548A1 (en) * | 2005-06-30 | 2007-01-11 | Whitehead Institute | Progenitor cells and uses thereof |
| CN101501187A (zh) * | 2006-06-06 | 2009-08-05 | 田纳西大学研究基金会 | 富含赘生干细胞的组合物及包含其的方法 |
| AU2008207945A1 (en) * | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| US11898160B2 (en) * | 2008-10-09 | 2024-02-13 | Minerva Biotechnologies Corporation | Method for maintaining pluripotency in cells |
| CA2830503A1 (en) * | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| US10731134B2 (en) * | 2011-05-27 | 2020-08-04 | Public University Corporation Yokohama City University | Production method for artificial cancer stem cell and induced differentiation method therefor |
| EP2768945B1 (en) * | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| TW201335372A (zh) * | 2011-11-30 | 2013-09-01 | Nat Cancer Ct | 誘導惡性幹細胞 |
| AU2013295811A1 (en) * | 2012-07-24 | 2015-03-12 | Minerva Biotechnologies Corporation | NME variant species expression and suppression |
| IL307628A (en) * | 2013-02-20 | 2023-12-01 | Minerva Biotechnologies Corp | Nme inhibitors and methods of using nme inhibitors |
-
2014
- 2014-08-12 WO PCT/US2014/050773 patent/WO2015023694A2/en not_active Ceased
- 2014-08-12 CN CN201480055352.5A patent/CN105764334B/zh active Active
- 2014-08-12 EP EP23160947.0A patent/EP4233536B1/en active Active
- 2014-08-12 AU AU2014306778A patent/AU2014306778B2/en active Active
- 2014-08-12 TW TW103127591A patent/TWI659210B/zh active
- 2014-08-12 CA CA2921187A patent/CA2921187A1/en active Pending
- 2014-08-12 EP EP14835875.7A patent/EP3038462B1/en active Active
- 2014-08-12 JP JP2016534802A patent/JP6640086B2/ja active Active
-
2016
- 2016-02-11 IL IL244093A patent/IL244093B/en unknown
-
2019
- 2019-08-23 JP JP2019152467A patent/JP6902577B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200429A patent/AU2021200429C1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527901A5 (enExample) | ||
| Rimmelé et al. | Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3 | |
| WO2022159892A1 (en) | Reprogrammable tnpb polypeptides and use thereof | |
| AU2021364399A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| JP2019047818A5 (enExample) | ||
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| AR102888A1 (es) | Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47 | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| JP7288853B2 (ja) | ゲノムネットワークを構築するための方法およびその使用 | |
| Kanarek et al. | Critical role for IL-1β in DNA damage-induced mucositis | |
| CY1119283T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii | |
| HRP20251062T1 (hr) | Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala | |
| BR112016006261A2 (pt) | camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas | |
| MX2015008754A (es) | Caracterizacion de un medicamento relacionado con acetato de glatiramer. | |
| EP4437094A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| WO2016007570A3 (en) | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof | |
| JP2020520680A5 (enExample) | ||
| EP4448744A2 (en) | Reprogrammable fanzor polynucleotides and uses thereof | |
| Meng et al. | ZFP580, a novel zinc-finger transcription factor, is involved in cardioprotection of intermittent high-altitude hypoxia against myocardial ischemia-reperfusion injury | |
| Holbrook et al. | Expanding the spectrum of pancreatic cancers responsive to vesicular stomatitis virus-based oncolytic virotherapy: challenges and solutions | |
| MacLean II et al. | The RHOX homeodomain proteins regulate the expression of insulin and other metabolic regulators in the testis | |
| Patrushev et al. | Mutations in mitochondrial DNA and approaches for their correction | |
| Lytrivi et al. | Diabetes mellitus and the key role of endoplasmic reticulum stress in pancreatic β cells | |
| CN116583599A (zh) | 可重编程IscB核酸酶及其用途 | |
| Pesce et al. | Endothelial and cardiac progenitors: boosting, conditioning and (re) programming for cardiovascular repair |